Expert View: No-Deal Brexit's Legal Fallout For Pharma
Dr Jonathan Atkinson, partner at the UK-based intellectual property law firm HGF Ltd, sums up key expectations around legal, patent-related and trademark aspects for pharma in the event of a "no-deal" Brexit, and highlights regulatory changes that could have a bearing on the deal value of UK-bound M&A activity.
You may also be interested in...
The BioIndustry Association’s latest Brexit webinar looked at issues such as companies’ drug filing strategies in a no-deal scenario as well as the costs that industry is likely to incur as a result of changes to regulatory processes.
Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.
Cipla’s generic of Merck & Co’s Proventil makes significant inroads in the US, with the Indian company confident that it has both a strong cost position and large capacity to take on competition. Pricing in the segment currently remains ‘respectable.’